Normal-flow virus filtration: detection and assessment of the endpoint in bioprocessing

被引:78
作者
Bolton, G
Cabatingan, M
Rubino, M
Lute, S
Brorson, K
Bailey, M
机构
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Millipore Corp, Billerica, MA 01821 USA
[3] US FDA, Ctr Drug Evaluat & Res, Bethesda, MD 20892 USA
关键词
bioprocessing; log (reduction value); murine minute virus; normal flow virus filtration; pore-plugging model; virus break-through;
D O I
10.1042/BA20050056
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The breakthrough of a model virus, bacteriophage, Phi X-174, through normal-flow virus filters was studied using both commercial process fluids and model feedstreams. The results indicate that (i) Phi X-174 is a reasonable model for a mammalian parvovirus [MMV (murine minute virus)] in virus filtration studies; (ii) Phi X-174 LRV [log (reduction value)] shows a better correlation with percentage flow decline compared with volume processed under a variety of conditions; (iii) although the extent of decline in virus LRV is dependent on the mechanism of filter fouling, the fouling mechanisms operative in a viral validation study are representative of those likely to be found under actual production conditions. The mechanism of LRV decline by many process streams was proposed to be due to selective plugging of small pores. A theoretical model as well as a predictive equation for LRV decline versus flow decay was derived; experimental results from filtration studies using pore-plugging feedstocks were consistent with the equation. As protein solutions may vary in their adsorptive versus plugging behaviour during filtration, an evaluation of the LRV-versus-flow-decay relationship on a biopharmaceutical-product-specific basis may be warranted.
引用
收藏
页码:133 / 142
页数:10
相关论文
共 21 条
[1]  
[Anonymous], 1998, QUAL GUID Q5A VIR SA
[2]   Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins [J].
Brorson, K ;
Sherrie, K ;
Lee, K ;
Hamilton, E ;
Stein, K ;
Xu, Y .
BIOTECHNOLOGY AND BIOENGINEERING, 2003, 82 (03) :321-329
[3]   Performance of a novel viresolve NFR virus filter [J].
Brough, H ;
Antoniou, C ;
Carter, J ;
Jakubik, J ;
Xu, Y ;
Lutz, H .
BIOTECHNOLOGY PROGRESS, 2002, 18 (04) :782-795
[4]  
CARTER J, 2002, EUR J PARENTER SCI, V7, P72
[5]   HIGH-TEMPERATURE SHORT-TIME HEAT INACTIVATION OF HIV AND OTHER VIRUSES IN HUMAN BLOOD-PLASMA [J].
CHARM, SE ;
LANDAU, S ;
WILLIAMS, B ;
HOROWITZ, B ;
PRINCE, AM ;
PASCUAL, D .
VOX SANGUINIS, 1992, 62 (01) :12-20
[6]   Generic/matrix evaluation of SV40 clearance by anion exchange chromatography in flow-through mode [J].
Curtis, S ;
Lee, K ;
Blank, GS ;
Brorson, K ;
Xu, Y .
BIOTECHNOLOGY AND BIOENGINEERING, 2003, 84 (02) :179-186
[7]  
Garnick RL, 1998, DEV BIOL STAND, V93, P21
[8]  
HERMIA J, 1982, T I CHEM ENG-LOND, V60, P183
[9]   MECHANISM OF REMOVING JAPANESE ENCEPHALITIS-VIRUS (JEV) AND GOLD PARTICLES USING CUPRAMMONIUM REGENERATED CELLULOSE HOLLOW-FIBER (I-BMM OR BMM) FROM AQUEOUS-SOLUTION CONTAINING PROTEIN [J].
HIRASAKI, T ;
NODA, T ;
NAKANO, H ;
ISHIZAKI, Y ;
MANABE, SI ;
YAMAMOTO, N .
POLYMER JOURNAL, 1994, 26 (11) :1244-1256
[10]   Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma [J].
Horowitz, B ;
Lazo, A ;
Grossberg, H ;
Page, G ;
Lippin, A ;
Swan, G .
VOX SANGUINIS, 1998, 74 :203-206